• 患者服务: 与癌共舞小助手
  • 微信号: yagw_help22

QQ登录

只需一步,快速开始

开启左侧

关于PD1在胆管的使用,请bluest给个建议

[复制链接]
5050 13 tracyzhou 发表于 2015-2-26 22:23:04 |
bluest  退休老干部 发表于 2015-3-4 22:09:55 | 显示全部楼层 来自: 北京朝阳
tracyzhou 发表于 2015-3-4 17:52
我主要看胆管的对靶向的耐药时间非常短,一旦停下来好像就会长得很快,需要不停尝试到有效药控制

是啊,胆管癌还是没有找到关键点
深度读帖后再提问,在线时间过短不予回复。
所有信息仅供参考!
lamya  初中一年级 发表于 2015-3-10 13:31:33 | 显示全部楼层 来自: 辽宁沈阳
有效缓解的办法真是太少,急人。
小金牛  小学六年级 发表于 2016-12-18 23:53:49 来自手机 | 显示全部楼层 来自: 山西忻州
请问后续有使用pd1吗
tk0083  小学三年级 发表于 2017-1-8 17:06:51 | 显示全部楼层 来自: 美国
本帖最后由 tk0083 于 2017-1-8 17:12 编辑

Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma
Abstract
Background

Program death 1 (PD-1) and its ligand (PD-L1) have been identified as potential therapeutic targets for solid and hematologic malignancies. The current study aimed to assess PD-L1 expression in intrahepatic cholangiocarcinoma (ICC) and relate clinical outcomes to its expression.

Methods

Formalin-fixed, paraffin-embedded tumor specimens were obtained for patients undergoing surgery at Johns Hopkins Hospital between 1991 and 2011. Immunohistochemistry was used to assess PD-L1 expression in tumor-associated macrophages (TAMs) and within the tumor front (TF).

Results

Of 54 tumor samples analyzed, 34 stained positive for PD-L1 expression on TAMs (TAMs+), and 39 stained positive for PD-L1 expression on cells within the tumor front (TF+). The TF+ patients were less likely to present with metastatic lymph nodes (N1 patients: 26.7 vs 7.7 %; p = 0.011), whereas all tumors with intrahepatic metastasis failed to demonstrate staining for PD-L1 around the tumor front (p = 0.020). Patients with tumors shown to be TAMs+ were less likely to present with multiple lesions (35.0 vs 8.8 %; p = 0.017). Patients with tumors exhibiting PD-L1 expression around the tumor front demonstrated a worse overall survival than TF patients (p = 0.008). Multivariable analysis showed that patients with tumors staining for PD-L1 in the tumor front had a 59.5 % reduced survival (TF− vs TF+: time ratio, 0.405; 95 % confidence interval, 0.215–0.761; p = 0.005).

Conclusion

Expression of PD-L1 was noted among a majority of patients, and PD-L1 expression within the tumor front was associated with a 60 % decreased survival. Future clinical trials are necessary to assess the safety and efficacy of anti-PD-L1 therapies among patients with ICC.

这边的数据是在54个样本里面34个TAMs为阳性,39个TF+为阳性

发表回复

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

  • 回复
  • 转播
  • 评分
  • 分享
帮助中心
网友中心
购买须知
支付方式
服务支持
资源下载
售后服务
定制流程
关于我们
关于我们
友情链接
联系我们
关注我们
官方微博
官方空间
微信公号
快速回复 返回顶部 返回列表